SRAGE: A useful biomarker in acute lung injury?

Critical Care Medicine

Volumn 39, Issue 3, 2011, Pages 589-590

  Creagh Brown, Benedict C ^a,b   Burke Gaffney, Anne ^a,b   Evans, Timothy W ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

acute lung injury; ARDS; RAGE; sepsis; systemic inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; PATTERN RECOGNITION RECEPTOR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; EDITORIAL; HUMAN; LUNG EDEMA; LUNG LAVAGE; OXYGEN TENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

EID: 79952123285     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31820a8350     Document Type: Editorial

References (14)

1. Levitt JE, Gould MK, Ware LB, et al: The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med 2009; 24:151-167.
2. Pittet JF, Mackersie RC, Martin TR, et al: Biological markers of acute lung injury: Prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155:1187-1205. (Pubitemid 27172758)
3. Jabaudon M, Futier E, Roszyk L, et al: Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 2011; 39:480-488.
4. Creagh-Brown BC, Quinlan GJ, Evans TW, et al: The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: An important therapeutic target? Intensive Care Med 2010; 36:1644-1656.
5. Uchida T, Shirasawa M, Ware LB, et al: Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173:1008-1015.
6. Calfee CS, Ware LB, Eisner MD, et al: Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63:1083-1089.
7. Bopp C, Hofer S, Weitz J, et al: sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147:79-83. (Pubitemid 351626081)
8. Su X, Looney MR, Gupta N, et al: Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol 2009; 297:L1-L5.
9. Ramasamy R, Yan SF, Schmidt AM: RAGE: therapeutic target and biomarker of the in- flammatory response-The evidence mounts. J Leukoc Biol 2009; 86:505-512.
10. Soop A, Sunden-Cullberg J, Albert J, et al: Adenosine infusion attenuates soluble RAGE in endotoxin-induced inflammation in human volunteers. Acta Physiol (Oxf) 2009; 197:47-53.
11. Brown LF, Fraser CG: Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem 2008; 45:518-519.
12. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-538.
13. Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575. (Pubitemid 43882352)
14. Papazian L, Forel JM, Gacouin A, et al: Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107-1116